Impact of Allogeneic Stem Cell Transplant on Safety and Outcomes of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Patients with Multiple Myeloma (MM)

Ayrton Bangolo; Behzad Amoozgar; Lili Zhang; Vignesh K Nagesh; Imranjot Sekhon; Simcha Weissman; David Vesole; Pooja Phull; Michele Donato; Noa Biran; David Siegel; Harsh Parmar

doi:10.20944/preprints202409.0529.v1

Submitted:

05 September 2024

Posted:

06 September 2024

You are already at the latest version

Abstract

Introduction Allogeneic stem cell transplantation (allo-SCT) has been used less frequently as a treatment modality in patients with MM. Allo-SCT may have the potential of long-term survival or even cure due to graft versus myeloma effect, however, its use continues to remain controversial given the toxicity profile related to infectious complications and graft versus host disease (GVHD). Concern for exacerbation of GVHD has been raised following re-infusion of CAR-T cells in patients with prior Allo-SCT. Ciltacabtagene autoleucel (Cilta-cel) and Idecabtagene vicleucel (Ide-cel) are two engineered CAR-T products targeting specific B-cell receptors that are approved by the FDA for the treatment of relapsed/refractory (R/R) MM. A recent retrospective study conducted by Htut et al, using data from CARTITUDE-1 trial, showed favorable efficacy and safety in patients who received Cilta-Cel with prior allo-SCT. We report our experience for patients with prior Allo-SCT who underwent therapy with CAR-T in the real world setting. Objective To evaluate the safety and efficacy of CAR-T therapy in patients with R/R MM with a history of allo-SCT. Methods We conducted a retrospective chart review of adult patients (age 18-70 years old) with R/R MM who had received CAR-T on an institutional IRB approved protocol. We collected data for the eligible patients from our institution's database. Safety outcomes included the incidence and severity of adverse events (AEs). AEs were graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE 5.0). Cytokine release syndrome (CRS) and immune effector associated neurotoxicity syndrome (ICANS) were graded as per the American Society for Transplantation and Cellular Therapy criteria. Efficacy outcomes included overall response rates (ORR), progression free survival (PFS). Survival analysis was performed using the Kaplan-Meir method including PFS. PFS was defined as time from initiation of treatment to progression of disease or death whichever occurred first. The IMW response criteria were utilized for response assessment. Results 8 out of 56 patients who received CAR-T (Cilta-cel or Ide-cel) had a prior allo-SCT. Pts with prior allo-SCT had received a median of 7 prior lines of therapy(LOT) compared with 5 prior LOT for pts who did not(non-Allo)(p=0.04). Median time of CAR-T infusion was 98.8 months following allo-SCT. 7 of 8 (85.7%) pts experienced CRS (any grade) in Allo-SCT vs. 37 of 48 pts (77.1%) in non-Allo (p=0.48); 1 pt with prior allo-SCT experienced HLH requiring intervention with anakinra. At a median follow-up of 4.8 months, 7 of 8 patients had a response (ORR= 87.5%) in allo-SCT vs. 75%(36 of 48) in non-Allo (p=0.4), mPFS was not reached in allo-SCT vs. 11.9-months in non-Allo (p=0.5), although f/u for our cohort was short. No TRM was observed in either group. None of the patients with prior allo-SCT experienced acute GVHD following CAR-T therapy. Baseline characteristics, safety and efficacy data are summarized in Table 1. Conclusion Our findings support the conclusion that prior Allo-SCT does not impact the safety and efficacy of CAR-T therapy in patients with R/R MM. More clinical studies with a higher number of subjects and longer duration of follow-up are warranted to further evaluate the impact of Allo-SCT on CAR-T therapy's safety and clinical outcome in patients with MM.

Keywords:

CART

;

Stem Cell Transplant

;

Safety

;

Cellular Therapy

Subject:

Medicine and Pharmacology - Oncology and Oncogenics

Introduction

The advent of chimeric antigen receptor T cell (CAR-T) therapy has drastically changed the treatment paradigm for relapsed/refractory multiple myeloma (R/R MM), providing a new therapeutic option for patients who have exhausted conventional treatments. CAR-T therapies, particularly Ciltacabtagene autoleucel (Cilta-cel) and Idecabtagene vicleucel (Ide-cel), have demonstrated impressive efficacy in targeting B-cell maturation antigen (BCMA) on malignant plasma cells, leading to notable improvements in both overall response rates (ORR) and progression-free survival (PFS) in patients who have undergone multiple prior lines of therapy [1,2]. These therapies have shown durable responses in many patients, even those with heavily pretreated and refractory disease, making them a cornerstone in the treatment of R/R MM. Despite these promising results, concerns remain regarding the safety and efficacy of CAR-T therapy in specific populations, particularly in patients with a history of allogeneic stem cell transplantation (allo-SCT).

Allo-SCT, which leverages the graft-versus-myeloma effect, is one of the few potentially curative options for multiple myeloma. However, it is associated with significant risks, including graft-versus-host disease (GVHD) and increased susceptibility to infections [3,4,5]. For these reasons, the use of allo-SCT in MM has been somewhat limited, and the potential interactions between allo-SCT and CAR-T therapy remain under investigation. Of particular concern is the possibility that the infusion of CAR-T cells into patients with prior allo-SCT could exacerbate or reinitiate GVHD, posing a severe threat to the patient’s health [6,7,8,9]. As CAR-T therapy becomes more widely used in R/R MM, understanding its safety and efficacy in patients with a prior allo-SCT is crucial to optimizing treatment strategies for this population.

The safety profile of CAR-T therapy in patients with previous allo-SCT is an area of intense interest due to the potential for heightened immune-related complications. GVHD, a condition in which the donor immune cells attack the recipient’s tissues, can be triggered or worsened by immune-modulating treatments like CAR-T therapy. Moreover, there is a concern that patients who have undergone allo-SCT may experience increased rates of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), which are well-documented side effects of CAR-T therapy [1,2]. Thus, determining the incidence and severity of these adverse events in this population is essential to improving the management of post-transplant patients receiving CAR-T.

Additionally, the efficacy of CAR-T therapy in the context of prior allo-SCT is another important consideration. Patients who have undergone allo-SCT typically have more aggressive or resistant disease, as they have often been heavily pretreated, and thus may not respond as robustly to subsequent therapies. However, CAR-T therapies targeting BCMA have demonstrated high ORRs in clinical trials across various patient subgroups, including those with high-risk cytogenetics and those refractory to multiple previous treatments [1,2]. Understanding whether this efficacy translates to the allo-SCT population is critical for guiding clinical decision-making and determining the appropriate sequencing of therapies in these complex cases.

Given these challenges, this study seeks to address the knowledge gap by providing real-world data on the safety and efficacy of CAR-T therapy in patients with a history of allo-SCT. By examining outcomes such as ORR, PFS, and adverse events in this unique subset of patients, this research aims to inform clinical practice and provide a clearer understanding of how to best integrate CAR-T therapy into the treatment algorithm for R/R MM patients with prior allo-SCT. The findings of this study will be particularly valuable for clinicians in determining the timing and appropriateness of CAR-T therapy in patients with a history of allo-SCT, as well as in identifying strategies to mitigate potential complications like GVHD and CRS.

In this retrospective analysis, we reviewed the outcomes of R/R MM patients who received CAR-T therapy following prior allo-SCT. Key endpoints such as ORR, PFS, and adverse event rates, including the incidence of CRS, ICANS, and GVHD, were evaluated to assess the safety and therapeutic benefit of CAR-T in this population. Through this analysis, we aim to provide a comprehensive overview of the risks and benefits of CAR-T therapy in patients with previous allo-SCT, contributing to the growing body of literature on this important topic and guiding future clinical practice in the management of R/R MM. Our study will offer valuable insights into the feasibility and safety of CAR-T therapy post-allo-SCT and help clinicians make more informed decisions regarding patient care.

This study is poised to offer critical insights into the impact of prior allo-SCT on the outcomes of CAR-T therapy, highlighting the importance of patient selection and risk management when integrating these therapies into the treatment landscape of R/R MM. Understanding these dynamics is vital for ensuring that CAR-T therapy is used safely and effectively in patients with complex treatment histories, ultimately improving outcomes and quality of life for patients with this challenging disease.

Methods

This retrospective cohort study was conducted at the John Theurer Cancer Center, Hackensack University Medical Center, to investigate the influence of prior allo-SCT on the safety and effectiveness of CAR-T therapy in patients with R/R MM. The study included a population of adult patients aged 18 to 70 years who had undergone CAR-T therapy using either Ciltacabtagene autoleucel or Idecabtagene vicleucel, two FDA-approved CAR-T products targeting the B-cell maturation antigen (BCMA). The time frame for CAR-T infusion spanned from February 2015 to July 2023. Among the cohort, patients with a history of allo-SCT were specifically identified to assess potential differences in outcomes compared to those without a prior allo-SCT.

Data were meticulously gathered through an exhaustive chart review, which encompassed patient demographics, clinical profiles, treatment history, and post-treatment outcomes. The evaluation of safety outcomes was a key focus, with the primary emphasis on the incidence and severity of adverse events (AEs). Adverse events were categorized and graded according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, which is a widely accepted standard for assessing the severity of AEs in clinical trials. Two significant toxicities often associated with CAR-T therapy—cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)—were of particular interest. These conditions were graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) criteria, a framework used to assess immune-related adverse events [10]. CRS is characterized by a systemic inflammatory response that can range from mild to life-threatening, while ICANS manifests as neurotoxic effects that may impair cognitive function, coordination, or motor skills.

In terms of efficacy, the study primarily measured overall response rates (ORR), which represents the proportion of patients achieving a partial or complete response to CAR-T therapy. Additionally, the proportion of patients reaching very good partial remission (VGPR) or better was assessed, offering a more refined measure of therapeutic success. Another key endpoint was progression-free survival (PFS), defined as the length of time from CAR-T infusion to either disease progression or death. PFS serves as a critical metric for gauging the durability of the treatment response in this heavily pretreated patient population.

Statistical analyses were employed to compare outcomes between the allo-SCT and non-allo-SCT groups. Categorical variables such as the incidence of adverse events and response rates were analyzed using the chi-square test, a statistical tool used to determine whether there is a significant association between categorical variables. For continuous variables like the number of prior lines of therapy or time to progression, the Mann-Whitney U test was applied. This non-parametric test is used when comparing differences between two independent groups, especially when the data does not necessarily follow a normal distribution. A p-value threshold of < 0.05 was considered statistically significant, meaning that any observed differences between the groups would have a less than 5% probability of being due to random chance alone.

To ensure robust and accurate statistical analyses, all data computations and survival analyses were conducted using R version 4.1.3, a highly flexible and widely used programming language for statistical computing and data visualization. The Kaplan-Meier method, which is commonly used for survival analysis, was employed to estimate the PFS and survival probabilities over time, providing a visual representation of patient outcomes and the durability of CAR-T therapy. This method is particularly useful in clinical studies where some patients may be lost to follow-up, as it allows for the estimation of survival while accounting for censored data.

By collecting and analyzing this comprehensive set of data, this study aims to provide valuable insights into the unique risks and benefits of administering CAR-T therapy to patients with a history of allo-SCT, contributing to a more nuanced understanding of the optimal use of CAR-T therapy in the treatment of relapsed/refractory multiple myeloma.

Results

In this study, we analyzed 56 patients diagnosed with relapsed/refractory multiple myeloma (R/R MM) who had undergone CAR-T therapy. Out of these, 8 patients (14.3%) had a previous history of allo-SCT. We observed a significantly higher median number of prior lines of therapy (LOT) in the allo-SCT group compared to those without allo-SCT. Specifically, patients with prior allo-SCT had undergone a median of 7 prior LOT (range 5-11), while the non-allo-SCT group had a median of 5 LOT (range 4-12), with this difference being statistically significant (p=0.04). Moreover, the median time from the initial diagnosis to CAR-T infusion was significantly longer in the allo-SCT cohort, with a median of 13.0 years compared to 7.7 years in the non-allo-SCT cohort (p=0.03). This suggests that patients with a history of allo-SCT had a more extensive and prolonged treatment history, potentially reflecting more aggressive or resistant disease courses.

In terms of safety outcomes, cytokine release syndrome (CRS), a common side effect of CAR-T therapy, was prevalent in both groups. CRS occurred in 87.5% (7 of 8) of the patients in the allo-SCT group, compared to 77.1% (37 of 48) in the non-allo-SCT group (p=0.48), demonstrating that the incidence of CRS did not significantly differ between the two groups. Importantly, none of the patients in the allo-SCT group developed severe (grade III or higher) CRS, while one patient in the non-allo-SCT group experienced grade III or higher CRS (p=0.6), indicating that the prior allo-SCT did not exacerbate the severity of this adverse event. Additionally, immune effector cell-associated neurotoxicity syndrome (ICANS), another significant side effect of CAR-T therapy, was not observed in any patients in the allo-SCT group. In contrast, 14.6% of patients in the non-allo-SCT group experienced ICANS, with 6.3% developing grade III or higher ICANS, though this difference was not statistically significant (p=0.1). These results suggest that patients with prior allo-SCT do not appear to be at heightened risk for severe adverse events such as CRS or ICANS compared to those without prior allo-SCT.

Regarding efficacy, the overall response rate (ORR) in the allo-SCT group was an encouraging 87.5%, with 75% of patients achieving very good partial remission (VGPR) or better. In the non-allo-SCT group, the ORR was slightly lower at 75%, with 57.5% of patients achieving VGPR or better. Although the ORR was numerically higher in the allo-SCT group, the difference between the two groups was not statistically significant (p=0.4). This suggests that prior allo-SCT does not negatively affect the overall efficacy of CAR-T therapy in terms of response rates. Furthermore, median progression-free survival (PFS) was not reached in the allo-SCT group at the time of analysis, while in the non-allo-SCT group, the median PFS was 11.9 months (p=0.5). This may suggest that patients with prior allo-SCT could potentially experience more durable responses, although the follow-up period for the study was relatively short and further follow-up is needed to confirm these observations.

Finally, no treatment-related mortality (TRM) was observed in either group during the study’s follow-up period, further emphasizing the overall safety of CAR-T therapy in this cohort. Additionally, none of the patients in the allo-SCT group developed acute graft-versus-host disease (GVHD) following CAR-T therapy, a concern in patients with prior allo-SCT. These findings indicate that CAR-T therapy can be administered safely in patients with prior allo-SCT without exacerbating risks of acute GVHD or other severe complications. Nonetheless, the relatively small sample size of patients with prior allo-SCT and the short follow-up period underscore the need for larger studies with longer follow-up to confirm these results and provide a more comprehensive understanding of the long-term safety and efficacy of CAR-T therapy in this unique patient population.

Discussion

In this study of 56 patients with R/R MM treated with CAR-T therapy, 8 had a history of prior allo-SCT. The allo-SCT group had a significantly higher median number of prior LOT and a longer median time from diagnosis to CAR-T infusion compared to the non-allo-SCT group. Safety outcomes showed a high incidence of CRS in both groups, with no severe CRS in the allo-SCT group. No ICANS was observed in the allo-SCT group. Efficacy outcomes demonstrated a slightly higher ORR in the allo-SCT group, though the difference was not statistically significant. Median PFS was not reached in the allo-SCT group at the time of analysis. No treatment-related mortality or GVHD was observed following CAR-T therapy in the allo-SCT group, suggesting that prior allo-SCT does not negatively impact the safety or efficacy of CAR-T therapy in this patient population.

These findings are significant given the evolving role of CAR-T therapy in this patient population, where previous treatment modalities, such as allo-SCT, have traditionally been associated with high risks of GVHD and other complications [1,11]. Our analysis contributes to a growing body of evidence suggesting that CAR-T therapy can be safely administered in patients with a history of allo-SCT, without exacerbating the risks of GVHD or other severe adverse events.

The incidence of CRS observed in our study was consistent with prior reports, highlighting the commonality of this side effect in CAR-T therapy [13]. However, it is notable that no severe (grade III or higher) CRS was observed in the allo-SCT group, despite the higher baseline risk profile associated with this cohort. This aligns with findings from earlier studies, such as those by Raje et al. and Cohen et al., which also reported manageable CRS in CAR-T-treated patients with multiple myeloma [1,11]. The absence of ICANS in the allo-SCT group further underscores the safety of CAR-T therapy in this context, a finding that parallels results from the CARTITUDE-1 trial, where neurotoxicity was generally low in multiple myeloma patients [13].

Efficacy outcomes in our study demonstrated an ORR of 87.5% in the allo-SCT group, with 75% of patients achieving VGPR or better. These results are particularly encouraging given the heavily pretreated nature of the patient population, who had a median of 7 prior LOT. This response rate is comparable to, if not slightly better than, that observed in the broader CAR-T population, where ORRs typically range from 70% to 90% [2,14]. Our findings suggest that prior allo-SCT does not compromise the efficacy of CAR-T therapy, which remains robust even in the context of multiple prior treatments.

The PFS outcomes, with a median PFS not reached in the allo-SCT group, also suggest a durable response to CAR-T therapy in this subset of patients. This observation is consistent with other studies, such as the phase 2 KarMMa trial, which reported prolonged PFS in patients treated with CAR-T therapy, despite prior high-risk features [15]. However, the relatively short follow-up period in our study limits the ability to draw definitive conclusions about long-term outcomes. Nonetheless, the lack of TRM and the absence of acute GVHD following CAR-T therapy in the allo-SCT group provide further reassurance about the safety profile of this approach.

One potential concern with administering CAR-T therapy to patients with a history of allo-SCT is the risk of exacerbating GVHD, a life-threatening complication that could undermine the benefits of the therapy. Interestingly, none of the patients in our study who had undergone allo-SCT experienced acute GVHD following CAR-T therapy. This aligns with recent reports suggesting that CAR-T cells may have limited alloreactivity, thereby reducing the risk of GVHD exacerbation [16,17,18,19]. The underlying mechanisms for this observation are not fully understood but may be related to the specificity of CAR-T cells for tumor antigens, which spares normal tissues, including those potentially targeted during GVHD [4,20,21,22].

Our findings contribute to the ongoing debate about the optimal sequencing of therapies in R/R MM, particularly in patients with prior allo-SCT. While allo-SCT remains a potentially curative option for some patients, its use has declined due to the availability of less toxic, yet highly effective, alternatives such as CAR-T therapy [23,24,25]. Our data suggest that CAR-T therapy can be effectively integrated into the treatment paradigm for patients with a history of allo-SCT, without compromising safety or efficacy.

Despite these promising results, our study has several limitations. First, the retrospective nature of the analysis introduces inherent biases, including selection bias and the potential for incomplete data capture. Second, the small sample size of the allo-SCT group limits the generalizability of our findings and highlights the need for larger, prospective studies to validate our results.

Table 1. Demographic and Clinicopathologic characteristics of patients that received CART.

Variables	Allo-SCT	Non-Allo	P-value
No of patients	8 (14.3%)	48 (85.7%)
Male (%)	5 (62.5%)	27 (56.2%)	0.7
Median age in yrs (IQR)	57.9 (53.2-66.3)	70.6 (65.1-76.6)	0.02
Median prior LOT (range)	7 (5-11)	5 (4-12)	0.04
Median time from diagnosis to CAR-T in yrs (IQR)	13.0 (7.5-15.3)	7.7 (4.8-10.2)	0.03
High Risk FISH (%)	3* (50%)	25* (59.5%)	0.7
ISS stage II or III (%)	4 (50%)	21** (63.6%)	0.48
Triple refractory (%)	8(100%)	44 (91.7%)	0.3
CRS (any grade)	7(87.5%)	37 (77.1%)	0.48
CRS (GIII or higher)	0 (0%)	1 (2.1%)	0.6
ICANS (any grade)	0 (0%)	7 (14.6%)	0.1
ICANS (GIII or higher)	0 (0%)	3 (6.3%)	0.3
ORR (%)	7 (87.5%)	36 (75%)	0.4
VGPR or better (%)	6 (75%)	37(57.5%)	0.3
Median PFS (months)	Not Reached	11.9	0.5

IQR=Interquartile range; LOT= Lines of treatment; ISS= International staging system; CRS= Cytokine release syndrome; GIII= Grade III; ICANS= Immune effector cell neurotoxicity syndrome; ORR= Overall response rate; VGPR= Very good partial remission; PFS= Progression free survival.

Conclusion

In conclusion, this study demonstrates that CAR-T therapy can be safely administered to patients with R/R MM who have a history of allo-SCT. The findings indicate that prior allo-SCT does not compromise the safety or efficacy of CAR-T therapy, as evidenced by the comparable ORR and PFS between patients with and without prior allo-SCT. Notably, the incidence of severe CRS and ICANS was low, and no TRM or acute GVHD was observed following CAR-T therapy in the allo-SCT group. These results suggest that CAR-T therapy remains a viable and effective option for heavily pretreated R/R MM patients, even in those with a complex treatment history that includes allo-SCT. However, larger prospective studies with longer follow-up periods are necessary to confirm these findings and to fully assess the long-term outcomes of CAR-T therapy in this patient population.

Author Contributions

Ayrton Bangolo, Behzad Amoozgar, Lili Zhang, Vignesh K. Nagesh, Imranjot Sekhon, Simcha Weissman, David Vesole; Pooja Phull, Michele Donato, Noa Biran and David Siegel wrote and edited the manuscript. Harsh Parmar revised and approved the final version and is the article’s guarantor. All authors certify that they contributed sufficiently to the intellectual content and data analysis. Each author has reviewed the final version of the manuscript and approves it for publication.

Funding Sources

No Funding was received.

Institutional Review Board Statement

Internal Review Board (IRB) approval was obtained on 02/08/2022, IRB ID number STUDY00000010, and Pro IRB number Pro2022-0512.

Informed Consent Statement

Patients informed consent was obtained.

Data Availability Statement

The data utilized during this submission is available upon request from the corresponding author.

Conflicts of Interest Statement

No potential conflict of interest was reported by the authors.

References

Raje, N.; Berdeja, J.; Lin, Y.; Siegel, D.; Jagannath, S.; Madduri, D.; et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine 2019, 38018, 1726–1737. [Google Scholar] [CrossRef] [PubMed]
Munshi, N.C.; Anderson, L.D.; Shah, N.; Madduri, D.; Berdeja, J.; Lonial, S.; et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine 2021, 3848, 705–716. [Google Scholar] [CrossRef] [PubMed]
Htut, M.; Dhakal, B.; Cohen, A.D.; Martin, T.; Berdeja, J.G.; Usmani, S.Z.; et al. Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study. Clin Lymphoma Myeloma Leuk 2023, 2312, 882–888. [Google Scholar] [CrossRef] [PubMed]
Holstein, S.A.; McCarthy, P.L. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. Drugs 2017, 775, 505–520. [Google Scholar] [CrossRef] [PubMed]
Zeiser, R.; Blazar, B.R. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. New England Journal of Medicine 2017, 37726, 2565–2579. [Google Scholar] [CrossRef]
Wudhikarn, K.; Mailankody, S.; Smith, E.L. Future of CAR T cells in multiple myeloma. Hematology Am Soc Hematol Educ Program 2020, 20201, 272–279. [Google Scholar] [CrossRef]
Shah, N.N.; Fry, T.J. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol 2019, 166, 372–385. [Google Scholar] [CrossRef]
Hill, G.R.; Betts, B.C.; Tkachev, V.; Kean, L.S.; Blazar, B.R. Current Concepts and Advances in Graft-Versus-Host Disease Immunology. Annu Rev Immunol 2021, 39, 19–49. [Google Scholar] [CrossRef]
Brudno, J.N.; Kochenderfer, J.N. Toxicities of chimeric antigen receptor T cells: Recognition and management. Blood 2016, 12726, 3321–3330. [Google Scholar] [CrossRef]
Lee, D.W.; Santomasso, B.D.; Locke, F.L.; Ghobadi, A.; Turtle, C.J.; Brudno, J.N.; et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biology of Blood and Marrow Transplantation 2019, 254, 625–638. [Google Scholar] [CrossRef]
Cohen, A.D.; Garfall, A.L.; Stadtmauer, E.A.; Melenhorst, J.J.; Lacey, S.F.; Lancaster, E.; et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest 2019, 1296, 2210–2221. [Google Scholar] [CrossRef] [PubMed]
Usmani, S.Z.; Berdeja, J.G.; Jakubowiak, A.; Agha, M.; Cohen, A.D.; Madduri, D.; et al. UPDATED RESULTS FROM THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA. Hematology, Transfusion and Cell Therapy 2021, 43, S272. [Google Scholar] [CrossRef]
Usmani, S.Z.; Berdeja, J.G.; Madduri, D.; Jakubowiak, A.J.; Agha, M.E.; Cohen, A.D.; et al. Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1. Journal of Clinical Oncology 2021, 39, 8005. [Google Scholar] [CrossRef]
Chekol Abebe, E. , Yibeltal Shiferaw, M., Tadele Admasu, F., & Asmamaw Dejenie, T. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Frontiers in Immunology 2022, 13, 991092. [Google Scholar] [CrossRef]
Minakata, D.; Ishida, T.; Ando, K.; Suzuki, R.; Tanaka, J.; Hagiwara, S.; et al. Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma. Int J Hematol 2023, 1175, 729–737. [Google Scholar] [CrossRef]
Wei, J.; Han, X.; Bo, J.; Han, W. Target selection for CAR-T therapy. Journal of Hematology & Oncology 2019, 121, 62. [Google Scholar]
Zhang, X.; Zhu, L.; Zhang, H.; Chen, S.; Xiao, Y. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Front Immunol 2022, 13, 927153. [Google Scholar] [CrossRef]
Sun, W.; Liang, A.B.; Huang, H.; Huang, X.J. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience. Haematologica 2023, 1088, 2011–2028. [Google Scholar] [CrossRef] [PubMed]
Li, J.; Li, W.; Huang, K.; Zhang, Y.; Kupfer, G.; Zhao, Q. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: Lessons learned and strategies for moving forward. Journal of Hematology & Oncology 2018, 111, 22. [Google Scholar]
Benmebarek, M.R.; Karches, C.H.; Cadilha, B.L.; Lesch, S.; Endres, S.; Kobold, S. Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. Int J Mol Sci 2019, 20. [Google Scholar] [CrossRef]
Zahid, A.; Siegler, E.L.; Kenderian, S.S. CART Cell Toxicities: New Insight into Mechanisms and Management. Clin Hematol Int 2020, 24, 149–155. [Google Scholar] [CrossRef] [PubMed]
Fischer, J. W. , & Bhattarai, N. CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities. Frontiers in Immunology 2021, 12, 693016. [Google Scholar] [CrossRef] [PubMed]
Greil, C.; Engelhardt, M.; Finke, J.; Wäsch, R. Allogeneic Stem Cell Transplantation in Multiple Myeloma. Cancers (Basel) 2021, 14. [Google Scholar] [CrossRef] [PubMed]
Schmidt, W.M.; Perera, N.D.; Buadi, F.K.; Hayman, S.R.; Kumar, S.K.; Dispenzieri, A.; et al. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma. Blood Cancer Journal 2023, 131, 126. [Google Scholar] [CrossRef]
Claveau, J.S.; Buadi, F.K.; Kumar, S. Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma. Oncol Ther 2022, 101, 105–122. [Google Scholar] [CrossRef]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.